Cabometyx EU

Cabometyx in Europe

This is a promotional website intended for Healthcare Professionals in EU, excluding France

References (CABOMETYX® HCC)

  1. CABOMETYX® Summary of Product Characteristics.
  2. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.Br J Cancer. 2009;100(9):1385-92.
  3. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41-8.
  4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
  5. Firtina Karagonlar Z, Koc D, Iscan E, et al. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016;107(4):407-16.
  6. Yakes FM, Chen J, Tan, J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-308.
  7. Lee HJ, Jeng YM, Chen YL, et al. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 2013;35(4):769-75.
  8. Liu J, Wang K, Yan Z, et al. Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma. PLoS ONE. 2016;11(5):e0154767.
  9. Dengler M, Staufer K, Huber H, et al.Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget. 2017;8(28): 46234-48
  10. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54-63.
  11. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl.4):iv238–55.
  12. ESMO. eUpdate: Hepatocellular Carcinoma Algorithms. Available at https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Hepatocellular-Carcinoma/eUpdate-Treatment-Algorithms [Accessed July 16, 2019].
  13. Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
  14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Hepatobiliary Cancers. Version 2.2019 – March 2019. Available at https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf [Accessed July 16, 2019].

 

 

© Ipsen Group 2019 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A EU HEALTHCARE PROFESSIONAL

I AM A FRENCH HEALTHCARE PROFESSIONAL

I AM NOT A EU HEALTHCARE PROFESSIONAL